TheraRadar
Data updated: May 26, 2026

LUVOX CR (fluvoxamine maleate)

CNS Approved 2008-02-28
1
Indication
--
Phase 3 Trials
18
Years on Market

Details

Status
Discontinued
First Approved
2008-02-28
Routes
ORAL
Dosage Forms
CAPSULE, EXTENDED RELEASE

Companies

Active Ingredient: FLUVOXAMINE MALEATE

LUVOX CR Approval History

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
16 FDA actions from 2008 to 2017
Jan 2017 SUPPL
Label · Labeling
Jul 2014 SUPPL
Label · Labeling
Nov 2012 SUPPL
Label · Labeling

What LUVOX CR Treats

1 FDA approvals

Originally approved for its first indication in 2008 .

  • Other (1)
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT01933919 results posted M13-970 Ph 3 completed A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LUVOX CR FDA Label Details

Track LUVOX CR with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.